evipedia.ai
← Back

Phosphatidylinositol for Health & Longevity

Created on 11/06/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Phosphatidylinositol, a soy-derived supplement and fat-like cell-membrane building block, is proposed to raise "good" cholesterol and aid blood sugar control and liver health. Human evidence is thin and conflicted: the developer's larger trial did not confirm the cholesterol effect; other benefits rest on animal or related-compound research. Moderate amounts are generally well tolerated; the highest amount caused digestive upset, and soy-allergic people may react. No consistent evidence shows health benefits. (Full Review)

Protocol

12-week trial regimen
1 g or 3 g/day
In capsules after a dietary lead-in; 5 g/day was suspended for gastrointestinal intolerance
Time of day
With the main meals
No study compared timings; the lipid effect required food
Lecithin approach
De-oiled soy lecithin granules
An 11 g serving declares 1.0 g PI, the lowest trial dose; no study has tested this approach
Time to effect
Lipid changes
Within 2 weeks
In the positive trial; the 12-week trial found no significant change
Evaluation window
8–12 weeks
Absence of change by 12 weeks defines non-response

Benefits

Contraindications
  • Confirmed IgE-mediated soy allergy (positive soy-specific IgE or skin test with clinical reactions)
  • Active cancer treated with PI3K inhibitors
    •
Key Interactions
  • Food (meals): loss of the lipid effect when taken fasting
    •
Theoretical (inferred from mechanism)
  • Fibrates (fenofibrate, gemfibrozil): additive triglyceride lowering and HDL-C change
  • Statins (atorvastatin, rosuvastatin): additive lipid-modifying effects
  • Glucose-lowering drugs (metformin, insulin): increased risk of low blood glucose
  • Bile acid sequestrants (cholestyramine, colesevelam): may reduce PI absorption
  • Orlistat (over-the-counter Alli): additive gastrointestinal adverse effects
  • PI3K inhibitors (alpelisib, idelalisib): possible opposition to their effect on tumor growth signaling
  • Mood stabilizers (lithium, valproate): possible blunting of lithium's effect
  • Inositol supplements (myo-inositol, D-chiro-inositol): additive inositol load and glucose-lowering effects
  • Other phospholipids (lecithin, phosphatidylcholine): higher gastrointestinal upset risk
  • Niacin, fish oil, berberine: confound attribution of lipid changes to PI
  • Aerobic exercise and alcohol intake: confounding of lipid monitoring
    •

Risk & Side Effects

  • High:
  • Medium: Gastrointestinal intolerance at higher doses
    •
  • Low: Allergic reactions in soy-sensitive people
    •
  • Speculative: Promotion of growth signaling in cancer; liver fat from increased PI turnover
    •

Monitoring

Marker Target Why
HDL-C ≥40 mg/dL men, ≥50 mg/dL women; ≥60 mg/dL protective Main claimed effect
Triglycerides <150 mg/dL Fell in the 2-week trial
ApoA-I About 94–178 mg/dL men, 101–199 mg/dL women Rose in the 2-week trial
Fasting glucose 70–99 mg/dL Indirect, inositol-based effect
HOMA-IR No established target; track change from own baseline Indirect, inositol-based effect
Fasting insulin Not specified in the ER Needed for HOMA-IR
ALT 7–55 U/L Safety check; a rise above the upper limit stops use
AST Not specified in the ER Second liver enzyme, paired with ALT

Cadence: Baseline (two lipid measurements); lipids and apoA-I at 2–4 weeks and 12 weeks; glucose, insulin and ALT at 12 weeks, then every 6–12 months if continued

Qualitative Assessment

  • Gastrointestinal comfort: stool consistency, bloating, nausea, abdominal fullness
  • Allergic signs: itching, hives, lip or throat swelling
  • Mood stability: relevant for people taking lithium or valproate
  • Post-meal energy and appetite: subjective tracking; no PI data exist
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.